A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis
NCT00527410
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
9
Enrollment
INDUSTRY
Sponsor class
Stopped
Business Decision
Conditions
Leptomeningeal Carcinomatosis
Interventions
DRUG:
RTA 744
Sponsor
Biogen